학술논문
1094P Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S659-S659
Subject
Language
ISSN
0923-7534